According to Insys Therapeutics President and CEO, Saeed Motahari, these financial results have led them no choice but to turn “INSYS into a leader in pharmaceutical cannabinoids and spray technology.” This would be part of their strategy to come up with alternative means of profit to recover from the opioid-related losses.
No comments:
Post a Comment